Longitudinal Patient-Reported Outcome Trajectories in Long COVID: Findings From the STOP-PASC Clinical Trial - Takeaways - MDSpire

Longitudinal Patient-Reported Outcome Trajectories in Long COVID: Findings From the STOP-PASC Clinical Trial

  • By

  • Prasanna Jagannathan

  • Haley Hedlin

  • Jane W Liang

  • Blake Shaw

  • Evan Maestri

  • Michelle Lin

  • P J Utz

  • Upinder Singh

  • Linda N Geng

  • Hector Bonilla

  • October 8, 2025

  • 0 min

Share

  • 1

    Long COVID is a heterogeneous condition affecting various organ systems, with significant impacts on quality of life and function.

  • 2

    The STOP-PASC trial found no overall treatment effect of nirmatrelvir/ritonavir in adults with Long COVID.

  • 3

    Latent class trajectory modeling identified distinct symptom trajectories among participants, revealing clinical heterogeneity.

  • 4

    Improving symptom groups had shorter time since infection and higher baseline physical function compared to worsening groups.

  • 5

    The study highlights the need for validated, Long COVID-specific patient-reported outcome instruments for better therapeutic targeting.

Original Source(s)

Longitudinal Patient-Reported Outcome Trajectories in Long COVID: Findings From the STOP-PASC Clinical Trial

  • by Prasanna Jagannathan, Haley Hedlin, Jane W Liang, Blake Shaw, Evan Maestri, Michelle Lin, P J Utz, Upinder Singh, Linda N Geng, Hector Bonilla

  • October 8, 2025

Related Content

Multi-omics analysis of long COVID (post-COVID-19 condition) reveals persistent mitochondrial dysfunction, suppressed oxidative phosphorylation, and immune dysregulation

Self-administered digital vaccination decision-aids in primary care: A pilot study of COVID-19 vaccination in Atlanta, GA

Antibiotics May Not Help Mild COVID

A retrospective cohort study of more than 520,000 hospitalized patients found no clinically meaningful improvement in deterioration or mortality with early treatment targeting community-acquired pneumonia.